ViMRT
}  
 
Home   
< Docs   

 SARS_CoV_2 mutation literature information.


  Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India.
 PMID: 34896696       2022       Journal of infection and public health
Result: By performing the whole genome mutational analysis of 8592 SARS-CoV-2 strains collected during August 2020 to October 2021 from India, we identified 126 SARS-CoV-2 strains having new set of 11 coexisting mutations among 7 different genes: D279N and L353F in NSP4; V26F in NSP8; P323L in NSP12; D614G, P681H and V1230L in S glycoprotein; G172C in NS3; V62L in NS8; and R203K and G204R in N gene.


  Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.
 PMID: 34906769       2022       Biomedicine & pharmacotherapy
Introduction: A regular genome sequence is essential for viral specimens, particularly in the global context of a pandemic, since it aids to identify any emerging SARS-CoV-2 genetic strains, most importantly, with the development of the worldwide prevalence of D614G strain, which was linked with enhanced disease transmission however could not produce severe disease, the genetic transition was negligible at first.
Introduction: Consequently, ten mutations in the spike protein of B.1.617.2 strain, including T19R, (G142D*), 156/157del, R158G, L452R, T478K, D614G, P681R, and D950N were identified.
Introduction: In the  PMID: 34921776       2022       Cell host & microbe
Method: The Beta virus used in these studies contained the following mutations: D80A, D215G, L242-244 deleted, K417N, E484K, N501Y, D614G, A701V.|mg
Result: However, Alpha also contains the mutation D614G, which is not found in Victoria/Wuhan, we therefore went back and tested neutralization of a version of the early pandemic virus (B.1) containing the additional D614G mutation, using 17 Alpha sera.
Figure: (G) FRNT50 titers of 17 Alpha convalescent sera against Alpha and B.1 (D614G), analysis used the Wilcoxon matched-pairs signed rank sum test, and two-tailed p values were calculated; geometric means are indicated above each column.


  Pierce into Structural Changes of Interactions Between Mutated Spike Glycoproteins and ACE2 to Evaluate Its Potential Biological and Therapeutic Consequences.
 PMID: 34931119       2022       International journal of peptide research and therapeutics
Result: According to the results of the multiple sequence alignment, the mutations of the EPI_ISL_601443 variant were as follows: H69 deletion, V70 deletion, Y144 deletion, N501Y substitution, A570D substitution, D614G substitution, P681H substitution, T716I substitution, S982A substitution, and D1118H substitution.


  Mutation profile of SARS-CoV-2 genome in a sample from the first year of the pandemic in Colombia.
 PMID: 34933126       2022       Infection, genetics and evolution
Result: The spike glycoprotein mutation Result: The mutations p.Lys1191Asp (K1191D), p.Glu484Lys (E484K), p.Leu18Phe (L18F), p.Pro26Ser (P26S), p.His655Tyr (H655Y), p.Asp614Gly (D614G), that along with other nucleotide substitutions constitute some of the VOC and VOI, were also identified, but not necessarily defining a complete lineage of interest.


  Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta.
 PMID: 34937050       2022       Nature
Method: After 1.5 min of baseline equilibration, 5 min of association was conducted at 10-100 nM S(D614G), SAlpha or SBeta, followed by 5 min of dissociation in the same buffer, which was used for baseline equilibration.
Method: Isogenic variants with the Alpha spike (wt-SAlpha) or individual Alpha spike mutations were introduced into a wild-type SARS-COV-2 'Wuhan' backbone strain comprising the D614G amino acid change (wt-S614G), as described.
Method: SARS-CoV-2 S protein expression plasmids were constructed to encode the ectodomain of S protein S(D614G) or SAlpha (residues 1-1208, with a mutated furin cleavage site and


  Genomic characterization of the dominating Beta, V2 variant carrying vaccinated (Oxford-AstraZeneca) and nonvaccinated COVID-19 patient samples in Bangladesh: A metagenomics and whole-genome approach.
 PMID: 34939673       2022       Journal of medical virology
Abstract: Noteworthily, the receptor binding domain (RBD) region of S protein of all the isolates harbored similar substitutions including K417N, E484K, and N501Y that signify the Beta, while D614G, D215G, D80A, A67V, L18F, and A701V substitutions were commonly found in the non-RBD region of Spike proteins.


  Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
 PMID: 34953513       2022       Cell host & microbe
Abstract: We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2-naive and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses.
Introduction: For example, the mutation D614G in the S glycoprotein, which appeared very early in the pandemic, is now present in almost all circulating strains.
Result: As expected, none of the SARS-CoV-2-naive plasma samples collected at V0 were able to recognize the SARS-CoV-2 S<


  Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor.
 PMID: 34955621       2022       Journal of King Saud University. Science
Introduction: Substitution mutations like D614G, N501Y, Y453F, N439K/R, P681H, K417N/T, and E484K, as well as deletion mutations like DeltaH69/V70 and Delta242-244 are the most common in the spike protein.
Introduction: The D614G mutation enhanced viral proliferation and transmission as compared to wild-type viruses.


  Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model.
 PMID: 34959053       2022       Journal of infection and public health
Abstract: The sera from B.1.1.28.2 infected hamsters efficiently neutralized the D614G variant virus whereas 6-fold reduction in the neutralization was seen in case of D614G variant infected hamsters' sera with the B.1.1.28.2 variant.
Abstract: We report herewith the isolation of the P.2 variant (B.1.1.28.2)
Method: SARS-CoV-2 B.1 variant (D614G variant), NIV-2020-770 (GISAID identifier: EPI_ISL_420546) isolated from a patient's throat/nasal swab sample with a titre of 106.5 tissue culture infective dose 50 (TCID50)/mL was used for the pathogenicity comparison study in hamsters with the B.1.1.28.2 isolate (GISAID identifier: EPI_ISL_2013029).



Browser Board

 Co-occurred Entities




   Filtrator